Delaware's Supreme Court has granted an appeal by GlaxoSmithKline (GSK) and other drug manufacturers to challenge a lower court ruling that allows expert testimony linking the discontinued heartburn medication Zantac to cancer. Over 70,000 lawsuits are pending, alleging that Zantac's active ingredient, ranitidine, can degrade into the carcinogen NDMA. The litigation gained traction after the FDA's 2020 request for the drug's market withdrawal due to safety concerns. GSK argues that the scientific backing for the plaintiffs' claims is inadequate, citing various epidemiological studies that support their defense. The outcome of the appeal could significantly impact numerous lawsuits currently in Delaware courts. This development follows earlier dismissals of similar cases in federal court, where expert testimony was deemed unreliable.